logo-loader
viewMaxCyte Inc

MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

Proactive Research analyst Emma Ulker discusses the update this morning from MaxCyte Inc (LON:MXCT) on the expansion of its phase I clinical trial of MCY-M11 - its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers. Ulker says the move is a natural progression based on promising preliminary data from the study which was presented at the virtual meeting of the American Society of Clinical Oncology (ASCO) in May.

 

Read MaxCyte: Expanded prospects for CARMA

Quick facts: MaxCyte Inc

Price: 354 GBX

AIM:MXCT
Market: AIM
Market Cap: £273.15 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Market report: UK lockdown fears sink FTSE into a sea of red

The FTSE is in the red this Monday morning with fears prime minister, Boris Johnson, is reportedly considering a two-week mini-lockdown in England in a bid to stem the spread of the virus. We’ll find out later on this week. As a consequence - British Airways parent company, IAG, (LON:IAG) is...

22 hours, 43 minutes ago

2 min read